Improving glycemic control with insulin detemir using the 303 Algorithm in insulin naïve patients with type 2 diabetes: A subgroup analysis of the US PREDICTIVE 303 study

Current Medical Research and Opinion

Volumn 24, Issue 1, 2008, Pages 11-20

  Selam, Jean Louis ^a   Koenen, Christoph ^b   Weng, Wayne ^c   Meneghini, Luigi ^d  

^a Diabetes Research Center   (United States)

^b NOVO NORDISK A S   (Denmark)

^c NOVO NORDISK INC   (United States)

^d UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

Insulin detemir; Insulin titration; Insulin na ve; Long acting insulin analog; PREDICTIVE 303; Type 2 diabetes

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; INSULIN DETEMIR;

ADD ON THERAPY; ADULT; ALGORITHM; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; GLYCEMIC CONTROL; GLYCOSYLATION; HUMAN; HYPOGLYCEMIA; MAJOR CLINICAL STUDY; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT CARE; PHYSICIAN; POST HOC ANALYSIS; RANDOMIZED CONTROLLED TRIAL; UNITED STATES;

AGED; ALGORITHMS; BLOOD GLUCOSE; BODY WEIGHT; CIRCADIAN RHYTHM; DIABETES MELLITUS, TYPE 2; DRUG DOSAGE CALCULATIONS; FASTING; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN; MALE; MIDDLE AGED; UNITED STATES;

EID: 38549131326     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079907X242755     Document Type: Conference Paper

References (26)

1. American Diabetes Association. Clinical Practice Recommendations 2007. Diabetes Care 2007;30:S1-103
2. Meneghini L. Why and how to use insulin therapy earlier in the management of type 2 diabetes. South Med J 2007;100:164-74
3. Writing team for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Effect of intensive therapy on the microvascular complications of type 1 diabetes mellitus. JAMA 2002;287:2563-9
4. Peyrot M, Rubin RR, Lauritzen T, et al. Resistance to insulin therapy among patients and providers. Results of the cross-national Diabetes, Attitudes, Wishes, and Needs (DAWN) study. Diabetes Care 2005;28:2673-9
5. Davis SN, Renda SM. Psychological insulin resistance. Overcoming barriers to starting insulin therapy. Diabetes Educ 2006;32:146S-52
6. Novo Nordisk Inc. Levemir (insulin detemir [rDNA origin] injection) prescribing information. Princeton, New Jersey, USA. 2005
7. Home P, Kurtzhals P. Insulin detemir: from concept to clinical experience. Expert Opin Pharmacother 2006;7:325-43
8. Kurtzhals P. Engineering predictability and protraction in a basal insulin analogue: the pharmacology of insulin detemir. Int J Obes 2004;28:S23-8
9. Heise T, Pieber TR. Towards peakless, reproducible and long-acting insulins. An assessment of the basal analogues based on isoglycaemic clamp studies. Diabetes Obes Metab 2007;9:648-59
10. Klein O, Lynge J, Endahl L, et al. Albumin-bound basal insulin analogues (insulin detemir and NN344): comparable time-action profiles but less variability than insulin glargine in type 2 diabetes. Diabetes Obes Metab 2007;9:290-9
11. Heise T, Nosek L, Ronn BB, et al. Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in subjects with type 1 diabetes. Diabetes 2004;53:1614-20
12. Haak T, Tiengo A, Draeger E, et al. Lower within-subject variability of fasting blood glucose and reduced weight gain with insulin detemir compared to NPH insulin in patients with type 2 diabetes. Diabetes Obes Metab 2005;7:56-64
13. Hermansen K, Davies M, Derezinski T, et al. A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naïve people with type 2 diabetes. Diabetes Care 2006;29:1269-74
14. Philis-Tsimikas A, Charpentier G, Clauson P, et al. Comparison of once-daily insulin detemir with NPH insulin added to a regimen of oral antidiabetic drugs in poorly controlled type 2 diabetes. Clin Ther 2006;28:1569-81
15. Raslova K, Bogoev M, Raz I, et al. Insulin detemir and insulin aspart: a promising basal-bolus regimen for type 2 diabetes. Diabetes Res Clin Pract 2004;66:193-201
16. Rosenstock J, Davies M, Home PD, et al. Insulin detemir added to oral anti-diabetic drugs in type 2 diabetes provides glycemic control comparable to insulin glargine with less weight gain. Diabetes 2006;55:A132
17. Meneghini L, Koenen C, Rojas P, et al. Efficacy and safety of insulin detemir in a large cohort of patients with type 2 diabetes using a simplified self-adjusted dosing guideline - results of the PREDICTIVE 303 Study. Diabetes 2007;56:A51
18. Danesh J, Wheeler JG, Hirschfield GM, et al. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med 2004;350:1387-97
19. Pearson TA, Mensah GA, Alexander RW, et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 2003;107:499-511
20. Rhee MK, Slocum W, Ziemer DC, et al. Patient adherence improves glycemic control. Diabetes Educ 2005;31:240-50
21. Dornhorst A, Luddeke H-J, Sreenan S, et al. Safety and efficacy of insulin detemir in clinical practice: 14-week follow-up data from type 1 and type 2 diabetes patients in the PREDICTIVE European cohort. Int J Clin Pract 2007;61:523-8
22. Meneghini L, Rosenberg KH, Koenen C, et al. Insulin detemir improves glycemic control with less hypoglycemia and no weight gain in patients with type 2 diabetes who were insulin naive or treated with NPH or insulin glargine: clinical practice experience from a German subgroup of the PREDICTIVE study. Diabetes Obes Metab 2007;9:418-27
23. Riddle MC, Rosenstock J, Gerich J, on behalf of the Insulin Glargine 4002 Study Investigators. The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care 2003;26:3080-6
24. Yki-Jarvinen H, Kauppinen-Makelin R, Tiikkainen M, et al. Insulin glargine or NPH combined with metformin in type 2 diabetes: the LANMET study. Diabetologia 2006;49:442-51
25. Selam J-L, Koenen C, Merilainen M, Meneghini L. Insulin detemir enables obese patients to improve glycemic control without weight gain. American Diabetes Association 2007 Scientific Meeting. 2007;2260-PO
26. Bray GA, Bellanger T. Epidemiology, trends, and morbidities of obesity and the metabolic syndrome. Endocrine 2006;29:109-17